Literature DB >> 24787293

Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function.

Ubaldo Martinez-Outschoorn1, Federica Sotgia2, Michael P Lisanti2.   

Abstract

Metabolic synergy or metabolic coupling between glycolytic stromal cells (Warburg effect) and oxidative cancer cells occurs in human breast cancers and promotes tumor growth. The Warburg effect or aerobic glycolysis is the catabolism of glucose to lactate to obtain adenosine triphosphate (ATP). This review summarizes the main findings on this stromal metabolic phenotype, and the associated signaling pathways, as well as the critical role of oxidative stress and autophagy, all of which promote carcinoma cell mitochondrial metabolism and tumor growth. Loss of Caveolin 1 (Cav-1) and the upregulation of monocarboxylate transporter 4 (MCT4) in stromal cells are novel markers of the Warburg effect and metabolic synergy between stromal and carcinoma cells. MCT4 and Cav-1 are also breast cancer prognostic biomarkers. Reactive oxygen species (ROS) are key mediators of the stromal Warburg effect. High ROS also favors cancer cell mitochondrial metabolism and tumorigenesis, and anti-oxidants can reverse this altered stromal and carcinoma metabolism. A pseudo-hypoxic state with glycolysis and low mitochondrial metabolism in the absence of hypoxia is a common feature in breast cancer. High ROS induces loss of Cav-1 in stromal cells and is sufficient to generate a pseudo-hypoxic state. Loss of Cav-1 in the stroma drives glycolysis and lactate extrusion via HIF-1α stabilization and the upregulation of MCT4. Stromal cells with loss of Cav-1 and/or high expression of MCT4 also show a catabolic phenotype, with enhanced macroautophagy. This catabolic state in stromal cells is driven by hypoxia-inducible factor (HIF)-1α, nuclear factor κB (NFκB), and JNK activation and high ROS generation. A feed-forward loop in stromal cells regulates pseudo-hypoxia and metabolic synergy, with Cav-1, MCT4, HIF-1α, NFκB, and ROS as its key elements. Metabolic synergy also may occur between cancer cells and cells in distant organs from the tumor. Cancer cachexia, which is due to severe organismal metabolic dysregulation in myocytes and adipocytes, shares similarities with stromal-carcinoma metabolic synergy, as well. In summary, metabolic synergy occurs when breast carcinoma cells induce a nutrient-rich microenvironment to promote tumor growth. The process of tumor metabolic synergy is a multistep process, due to the generation of ROS, and the induction of catabolism with autophagy, mitophagy and glycolysis. Studying epithelial-stromal interactions and metabolic synergy is important to better understand the ecology of cancer and the metabolic role of different cell types in tumor progression.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24787293     DOI: 10.1053/j.seminoncol.2014.03.002

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  82 in total

1.  Adipocyte Metabolic Pathways Regulated by Diet Control the Female Germline Stem Cell Lineage in Drosophila melanogaster.

Authors:  Shinya Matsuoka; Alissa R Armstrong; Leesa L Sampson; Kaitlin M Laws; Daniela Drummond-Barbosa
Journal:  Genetics       Date:  2017-04-10       Impact factor: 4.562

2.  Control of mitochondrial function and cell growth by the atypical cadherin Fat1.

Authors:  Longyue L Cao; Dario F Riascos-Bernal; Prameladevi Chinnasamy; Charlene M Dunaway; Rong Hou; Mario A Pujato; Brian P O'Rourke; Veronika Miskolci; Liang Guo; Louis Hodgson; Andras Fiser; Nicholas E S Sibinga
Journal:  Nature       Date:  2016-11-09       Impact factor: 49.962

3.  A Transcript-Specific eIF3 Complex Mediates Global Translational Control of Energy Metabolism.

Authors:  Meera Shah; Dan Su; Judith S Scheliga; Tomáš Pluskal; Susanna Boronat; Khatereh Motamedchaboki; Alexandre Rosa Campos; Feng Qi; Elena Hidalgo; Mitsuhiro Yanagida; Dieter A Wolf
Journal:  Cell Rep       Date:  2016-07-28       Impact factor: 9.423

4.  Phosphorylase kinase β affects colorectal cancer cell growth and represents a novel prognostic biomarker.

Authors:  Guanghui Wang; Wenbin Shen; Chen-Ying Liu; Yun Liu; Tingyu Wu; Ximao Cui; Tong Yu; Yilian Zhu; Jinglue Song; Peng Du; Long Cui
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-08       Impact factor: 4.553

Review 5.  Metabolic pathways in obesity-related breast cancer.

Authors:  Kristy A Brown
Journal:  Nat Rev Endocrinol       Date:  2021-04-29       Impact factor: 43.330

6.  Three dimensional engineered models to study hypoxia biology in breast cancer.

Authors:  Vaishali Aggarwal; Oshin Miranda; Paul A Johnston; Shilpa Sant
Journal:  Cancer Lett       Date:  2020-06-20       Impact factor: 8.679

7.  Expression of caveolin-1 in breast cancer stroma as a potential prognostic biomarker of survival and progression: a meta-analysis.

Authors:  Xiuying Li; Jinfan Sun; Shuenqin Hu
Journal:  Wien Klin Wochenschr       Date:  2017-03-31       Impact factor: 1.704

Review 8.  Cell-surface G-protein-coupled receptors for tumor-associated metabolites: A direct link to mitochondrial dysfunction in cancer.

Authors:  Bojana Ristic; Yangzom D Bhutia; Vadivel Ganapathy
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-05-13       Impact factor: 10.680

9.  Hypoxia-induced autophagy contributes to radioresistance via c-Jun-mediated Beclin1 expression in lung cancer cells.

Authors:  Yan-Mei Zou; Guang-Yuan Hu; Xue-Qi Zhao; Tao Lu; Feng Zhu; Shi-Ying Yu; Hua Xiong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-10-16

10.  Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes.

Authors:  Andriy Marusyk; Doris P Tabassum; Michalina Janiszewska; Andrew E Place; Anne Trinh; Andrii I Rozhok; Saumyadipta Pyne; Jennifer L Guerriero; Shaokun Shu; Muhammad Ekram; Alexander Ishkin; Daniel P Cahill; Yuri Nikolsky; Timothy A Chan; Mothaffar F Rimawi; Susan Hilsenbeck; Rachel Schiff; Kent C Osborne; Antony Letai; Kornelia Polyak
Journal:  Cancer Res       Date:  2016-09-26       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.